Related references
Note: Only part of the references are listed.Lacidipine Prevents Scopolamine-Induced Memory Impairment by Reducing Brain Oxido-nitrosative Stress in Mice
Kunal Khurana et al.
NEUROTOXICITY RESEARCH (2021)
Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough
Upasana Ganguly et al.
FRONTIERS IN AGING NEUROSCIENCE (2021)
KYP-2047, an Inhibitor of Prolyl-Oligopeptidase, Reduces GlioBlastoma Proliferation through Angiogenesis and Apoptosis Modulation
Sarah Adriana Scuderi et al.
CANCERS (2021)
Novel Positive Allosteric Modulators of AMPA Receptors Based on 3,7-Diazabicyclo[3.3.1]nonane Scaffold
Mstislav I. Lavrov et al.
MOLECULAR NEUROBIOLOGY (2020)
Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A
Reinis Svarcbahs et al.
PHARMACOLOGICAL RESEARCH (2020)
Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications
Adela Simkova et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2020)
The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy
Tommi P. Kilpelainen et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
The Effect of Cyanopyrrolidine Derivatives on the Activity of Prolyl Endopeptidase, Acute Exudative Inflammation and Visceral Pain in Mice
E. A. Ivanova et al.
BIOCHEMISTRY MOSCOW-SUPPLEMENT SERIES B-BIOMEDICAL CHEMISTRY (2020)
Extracellular prolyl oligopeptidase derived from activated microglia is a potential neuroprotection target
Teemu A. Natunen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2019)
New tricks of prolyl oligopeptidase inhibitors - A common drug therapy for several neurodegenerative diseases
Reinis Svarcbahs et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Pharmacological investigation of quinoxaline-bisthiazoles as multitarget-directed ligands for the treatment of Alzheimer's disease
Sneha R. Sagar et al.
BIOORGANIC CHEMISTRY (2019)
Prolyl oligopeptidase regulates progesterone secretion via the ERK signaling pathway in murine luteal cells
Ping Xu et al.
MOLECULAR REPRODUCTION AND DEVELOPMENT (2019)
Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses
Xu-Qiao Chen et al.
FRONTIERS IN NEUROSCIENCE (2019)
Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors
Tommi P. Kilpelainen et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Targeted Covalent Inhibition of Prolyl Oligopeptidase (POP): Discovery of Sulfonylfluoride Peptidomimetics
Salvador Guardiola et al.
CELL CHEMICAL BIOLOGY (2018)
Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects
Toshiharu Nagatsu
JOURNAL OF NEURAL TRANSMISSION (2017)
Different effects of anxiolytics phenazepam and fabomotizole on dipeptidylpeptidase-IV plasma activity in patients with anxiety disorders
T. Syunyakov et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2017)
Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors
Katerina Babkova et al.
FUTURE MEDICINAL CHEMISTRY (2017)
Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture
Timo T. Myohanen et al.
NEUROSCIENCE LETTERS (2017)
Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?
Pekka T. Mannisto et al.
FRONTIERS IN AGING NEUROSCIENCE (2017)
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
Antoine Daina et al.
SCIENTIFIC REPORTS (2017)
New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro
Raj Kumar et al.
SCIENTIFIC REPORTS (2017)
Neuroinflammation in Alzheimer's disease: Current evidence and future directions
Valeria Calsolaro et al.
ALZHEIMERS & DEMENTIA (2016)
Prolyl Oligopeptidase Enhances α-Synuclein Dimerization via Direct Protein-Protein Interaction
Mari H. Savolainen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Solution phase synthetic approach to fellutamide B
Jhillu Singh Yadav et al.
TETRAHEDRON LETTERS (2015)
KYP-2047 Penetrates Mouse Brain and Effectively Inhibits Mouse Prolyl Oligopeptidase
Aaro J. Jalkanen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2014)
iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA Approach
Antoine Daina et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse
Mari H. Savolainen et al.
NEUROBIOLOGY OF DISEASE (2014)
Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers
Lana Dokleja et al.
NEUROSCIENCE LETTERS (2014)
Protein phosphatase 2A dysfunction in Alzheimer's disease
Jean-Marie Sontag et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2014)
Benzyloxycarbonyl-Methionyl-2(S)-Cyanopyrrolidine, a Prolyl Endopeptidase Inhibitor, Modulates Depression-Like Behavior of Rats in Forced Swimming Test and Activities of Proline-Specific Peptidases in the Brain Structures
N. A. Krupina et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2013)
Effect of Prolyl Endopeptidase Inhibitor Benzyloxycarbonyl-Methionyl-2(S)-Cyanopyrrolidine on the Course of Experimental Depressive Syndrome in Rats
N. N. Khlebnikova et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2013)
Effect of Prolyl Endopeptidase Inhibitor Benzyloxycarbonyl-Methionyl-2(S)-Cyanopyrrolidine on Activity of Proline-Specific Peptidases in Brain Structures of Rats with Experimental MPTP-Induced Depressive Syndrome
N. N. Khlebnikova et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2013)
PROLYL OLIGOPEPTIDASE COLOCALIZES WITH α-SYNUCLEIN, β-AMYLOID, TAU PROTEIN AND ASTROGLIA IN THE POST-MORTEM BRAIN SAMPLES WITH PARKINSON'S AND ALZHEIMER'S DISEASES
M. J. Hannula et al.
NEUROSCIENCE (2013)
Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold
Koen Jansen et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity
Oxana Ryabtsova et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease
T. T. Myohanen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Changes in Activity of Proline-Specific Peptidases in Rat Model for Dementia of Alzheimer's Type
G. A. Nazarova et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2012)
Effect of Imipramine and Prolyl Endopeptidase Inhibitor Benzyloxycarbonyl-Methionyl-2(S)-Cyanopyrrolidine on Activity of Proline-Specific Peptidases in the Brain of Rats with Experimental Anxious-Depressive Syndrome
N. N. Khlebnikova et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2012)
Design, Synthesis, and Antiviral Activity Evaluation of Phenanthrene-Based Antofine Derivatives
Ziwen Wang et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2012)
P2-Substituted N-Acylprolylpyrrolidine Inhibitors of Prolyl Oligopeptidase: Biochemical Evaluation, Binding Mode Determination, and Assessment in a Cellular Model of Synucleinopathy
Pieter Van der Veken et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Computational Prediction of Blood-Brain Barrier Permeability Using Decision Tree Induction
Claudia Suenderhauf et al.
MOLECULES (2012)
Different Interactions of Prolyl Oligopeptidase and Neurotensin in Dopaminergic Function of the Rat Nigrostriatal and Mesolimbic Pathways
I. Peltonen et al.
NEUROCHEMICAL RESEARCH (2012)
Brain Pharmacokinetics of Two Prolyl Oligopeptidase Inhibitors, JTP-4819 and KYP-2047, in the Rat
Aaro J. Jalkanen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2011)
Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner
T. T. Myohanen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Activities of Proline-Specific Peptidases in Brain Structures of Rats with Experimental Anxiety-Depressive State Caused by Administration of Dipeptidyl Peptidase IV Inhibitor in the Early Postnatal Period
E. Yu. Kushnareva et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2011)
Editorial [Hot Topic: Prolyl Oligopeptidase in Brain Function and Dysfunction (Guest Editor: J. Arturo Garcia-Horsman)]
J. Arturo Garcia-Horsman
CNS & Neurological Disorders-Drug Targets (2011)
Role of Prolyl Endopeptidase in Intracellular Transport and Protein Secretion
M. Morawski et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2011)
Prolyl Oligopeptidase, Inositol Phosphate Signalling and Lithium Sensitivity
Adrian J. Harwood
CNS & Neurological Disorders-Drug Targets (2011)
Interaction of Prolyl Oligopeptidase with α-Synuclein
Anne-Marie Lambeir
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2011)
Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
Anne Penttinen et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2011)
Association of Prolyl Oligopeptidase with Conventional Neurotransmitters in the Brain
Iida Peltonen et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2011)
Extracellular proteases in epilepsy
Katarzyna Lukasiuk et al.
EPILEPSY RESEARCH (2011)
Inhibition of prolyl oligopeptidase by KYP-2047 fails to increase the extracellular neurotensin and substance P levels in rat striatum
Aaro J. Jalkanen et al.
NEUROSCIENCE LETTERS (2011)
Different Effects of Scopolamine and Inhibition of Prolyl Oligopeptidase on Mnemonic and Motility Functions of Young and 8-to 9-Month-Old Rats in the Radial-Arm Maze
Iida Peltonen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2010)
GAP43 shows partial co-localisation but no strong physical interaction with prolyl oligopeptidase
Zoltan Szeltner et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Effects of Prolylendopeptidase Inhibitor Benzyloxycarbonyl-Methionyl-2(S)-Cyanopyrrolidine on Experimental Depressive Syndrome Development in Rats
N. N. Khlebnikova et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2009)
Effect of a Prolyl Endopeptidase Inhibitor Benzyloxycarbonyl-Alanyl-Proline on the Development of Experimental Depressive Syndrome in Rats
N. N. Khlebnikova et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2009)
Behavioral Changes in Rats Induced by a Dipeptidyl Peptidase IV Inhibitor Methionyl-2(S)-Cyanopyrrolidine: Experimental Model of Anxiety-Depression Disorder
N. A. Krupina et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2009)
Constrained Peptidomimetics Reveal Detailed Geometric Requirements of Covalent Prolyl Oligopeptidase Inhibitors
Janice Lawandi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity
Elena Di Daniel et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2009)
DIVERSE ROLES OF MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF METALLOPROTEINASES IN NEUROINFLAMMATION AND CEREBRAL ISCHEMIA
E. Candelario-Jalil et al.
NEUROSCIENCE (2009)
Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP)
Curt D. Haffner et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology
R. Liu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats
Aaro J. Jalkanen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2007)
On the role of prolyl oligopeptidase in health and disease
J. A. Garcia-Horsman et al.
NEUROPEPTIDES (2007)
Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors. (vol 49, pg 3521, 2006)
Zhonghua Pei et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors
JI Venäläinen et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion
I Schulz et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Organocatalysis with proline derivatives: improved catalysts for the asymmetric Mannich, nitro-Michael and aldol reactions
AJA Cobb et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2005)
Substrate-dependent competency of the catalytic triad of prolyl oligopeptidase
Z Szeltner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Effects of environmental enrichment on gene expression in the brain
C Rampon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties
P Ertl et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
